These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 14593091)

  • 1. Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups.
    Fish EW; Faccidomo S; Gupta S; Miczek KA
    J Pharmacol Exp Ther; 2004 Feb; 308(2):474-80. PubMed ID: 14593091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of action of antidepressants: new data from Escitalopram].
    Fabre V; Hamon M
    Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Escitalopram and citalopram: the unexpected role of the R-enantiomer].
    Jacquot C; David DJ; Gardier AM; Sánchez C
    Encephale; 2007; 33(2):179-87. PubMed ID: 17675913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
    Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
    Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the strychnine-sensitive glycine receptor in the anxiolytic effects of GlyT1 inhibitors on maternal separation-induced ultrasonic vocalization in rat pups.
    Komatsu H; Furuya Y; Sawada K; Asada T
    Eur J Pharmacol; 2015 Jan; 746():252-7. PubMed ID: 25435080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
    Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
    Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
    Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escitalopram: a unique mechanism of action.
    Bræstrup C; Sanchez C
    Int J Psychiatry Clin Pract; 2004; 8 Suppl 1():11-3. PubMed ID: 24930683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
    Hogg S; Michan L; Jessa M
    Neuropharmacology; 2006 Jul; 51(1):141-5. PubMed ID: 16678216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
    Chen F; Larsen MB; Sánchez C; Wiborg O
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):193-8. PubMed ID: 15695064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram: a review of its use in the management of major depressive disorder in adults.
    Garnock-Jones KP; McCormack PL
    CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.
    Kaminska K; Rogoz Z
    J Physiol Pharmacol; 2016 Jun; 67(3):471-80. PubMed ID: 27512008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Escitalopram for treatment of major depressive disorder in adults].
    Llorca PM; Brousse G; Schwan R
    Encephale; 2005; 31(4 Pt 1):490-501. PubMed ID: 16389716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
    Owens MJ; Knight DL; Nemeroff CB
    Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila.
    Dunham KE; Venton BJ
    J Neurochem; 2022 Sep; 162(5):404-416. PubMed ID: 35736504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.